Advertisement
Research Article| Volume 32, ISSUE 11, P1049-1054, December 01, 1992

Plasma prolactin as a predictor of relapse in drug-free schizophrenic outpatients

DOI:https://doi.org/10.1016/0006-3223(92)90067-A
Plasma prolactin as a predictor of relapse in drug-free schizophrenic outpatients
Previous ArticleNialamide, an MAO inhibitor, increases urinary excretion of endogenously produced bufotenin in man
Next ArticleEffect of m-Chlorophenylpiperazine on plasma homovanillic acid concentrations in healthy subjects
      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      A low plasma prolactin concentration has been reported to be associated with an increased risk of subsequent relapse in patients with schizophrenia. Prolactin concentration was measured in samples from stable schizophrenic men who were outpatients just prior to neuroleptic withdrawal. No relationship between prolactin concentration and time to subsequent relapse was found. Prolactin concentration may predict time to relapse only in populations characterized by specific demographic features or medication history.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Brown W.A.
        • Laughren T.
        Low serum prolactin and early relapse following neuroleptic withdrawal.
        Am J Psychiatry. 1981; 138: 237-239
        • Brown W.A.
        • Laughren T.P.
        Tolerance to the prolactin-elevating effect of neuroleptics.
        Psychiatry Res. 1981; 5: 317-322
        • Buchanan R.W.
        • Kirkpatrick B.
        • Summerfelt A.
        • Hanlon T.E.
        • Levine J.
        • Carpenter W.T.
        Clinical predictors of relapse following neuroleptic withdrawal.
        Biol Psychiatry. 1992; 32: 72-78
        • Carpenter W.T.
        • Hanlon T.E.
        • Heinrichs D.W.
        • et al.
        Continous versus targeted medication in schizophrenic outpatients: Outcome results.
        Am J Psychiatry. 1990; 147: 1138-1148
        • Chouinard G.
        • Jones B.D.
        • Annable L.
        Neuroleptic-induced supersensitivity psychosis.
        Am J Psychiatry. 1978; 135: 1409-1410
        • Davis J.M.
        Comparative doses and costs of antipsychotic medication.
        Arch Gen Psychiatry. 1976; 33: 858-861
        • Faraone S.V.
        • Curran J.P.
        • Laughren T.
        • Faltus F.
        • Johnston R.
        • Brown W.A.
        Neuroleptic bioavailability, psychosocial factors, and clinical status: A 1-year study of schizophrenic outpatients after dose reduction.
        Psychiatry Res. 1986; 19: 311-322
        • Frohman L.H.
        • Stachura M.E.
        Neuropharmacologic control of neuroendocrine function in man.
        Metabolism. 1975; 24: 211-234
        • Green A.I.
        • Faraone S.V.
        • Brown W.A.
        Prolactin shifts after neuroleptic withdrawal.
        Psychiatry Res. 1990; 32: 213-219
        • Heinrichs D.W.
        • Carpenter W.T.
        Prospective study of prodromal symptoms in schizophrenia relapse.
        Am J Psychiatry. 1985; 142: 371-373
        • Heinrichs D.W.
        • Carpenter W.T.
        Experience with a drug-free month in schizophrenic outpatients.
        Psychopharmacol Bull. 1985; 21: 117-119
        • Herz M.I.
        • Glazer W.
        • Mirza M.
        • Moster M.
        • Hafez H.
        Treating prodromal episodes to prevent relapse in schizophrenia.
        Br J Psychiatry. 1989; : 123-127
        • Jolley A.G.
        • Hirsch S.R.
        • McRink A.
        • Manchanda R.
        Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical outcome at one year.
        Bmj. 1989; 298: 985-990
        • Kirkpatrick B.
        • Buchanan R.W.
        • Maeda K.
        • Carpenter Jr., W.T.
        • Jauch D.
        • Tamminga C.A.
        Effect of neuroleptic withdrawal on plasma prolactin: A possible marker of receptor adaptation.
        Biol Psychiatry. 1989; 26: 131-138
        • Koenigsberg H.W.
        • Handley R.
        Expressed emotion: From predictive index to clinical construct.
        Am J Psychiatry. 1986; 143: 1361-1373
        • Laughren T.P.
        • Brown W.A.
        • Williams B.W.
        Serum prolactin and clinical state during neuroleptic treatment and withdrawal.
        Am J Psychiatry. 1979; 136: 108-110
        • Lieberman J.A.
        • Kane J.M.
        • Gadaletta D.
        • et al.
        Methylphenidate challenge tests and course of schizophrenia.
        Psychopharmacol Bull. 1985; 21: 123-129
        • Marder S.R.
        • Van Putten T.
        • Mintz J.
        • Lebell M.
        • McKenzie J.
        • May P.R.A.
        Low- and conventional-dose maintenance therapy with fluphenazine decanoate.
        Arch Gen Psychiatry. 1987; 44: 518-521
        • Rao M.L.
        • Brown W.A.
        Stability of serum neuroleptic and prolactin concentrations during short- and long-term treatment of schizophrenic patients.
        Psychopharmacology (Berl). 1987; 93: 237-242
        • Zander K.J.
        • Fischer B.
        • Zimmer R.
        • Ackenheil M.
        Long-term neuroleptic treatment of chronic schizophrenic patients: Clinical and biochemical effects of withdrawal.
        Psychopharmacology. 1981; 73: 43-47

      Article info

      Publication history

      Received in revised form: July 20, 1992
      Received: March 1, 1991

      Footnotes

      ☆Supported in part by NIMH grants MH-40279 and MH-35996.

      Identification

      DOI: https://doi.org/10.1016/0006-3223(92)90067-A

      Copyright

      © 1992 Published by Elsevier Inc.

      ScienceDirect

      Access this article on ScienceDirect

      The content on this site is intended for healthcare professionals.


      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties.


      RELX